Block Admission Application & Interim Review
02 Juni 2010 - 5:07PM
UK Regulatory
TIDMMDST
RNS Number : 9701M
Medicsight Plc
02 June 2010
+-----------------------------+-------------------------------+
| Press Release | 02 June 2010 |
+-----------------------------+-------------------------------+
Medicsight Plc
('Medicsight' or 'the Company')
Block Admission Application & Interim Review
Block admission return for the period 3 September 2009 to 31 May 2010
On 5 September 2008, a block admission was made to AIM for 11,731,667 ordinary
shares of 5 pence each in the Company ('Ordinary Shares') which may be issued
pursuant to the Company's share option schemes A-H.
On 5 March 2009, a block admission was made to AIM for 1,805,000 Ordinary Shares
which may be issued pursuant to the Company's share option schemes I.
On 9 September 2009, a block admission was made to AIM for 8,148,750 Ordinary
Shares which may be issued pursuant to the Company's share option schemes J and
K.
On 26 January 2010 share option scheme L was implemented. No options have yet
been exercised under this plan. Under share option scheme L 100,000 options were
issued at 8.5p being the closing price on 26 January 2010. The options will vest
in equal sixths over a period of 3 years starting from 26 January 2010.
Accordingly a block application has today been made for 100,000 Ordinary Shares
which may be issued pursuant to the Company's share option scheme L. All shares
expected to be admitted pursuant to the above applications shall rank pari passu
with the existing issued shares of the Company. It is expected that admission
will become effective on 8 June 2010.
During the period, the following changes to the block admissions occurred:
+----------------+------------+-----------+----------+-----------+-----------+
| Share option | No. of | No. of | No. of | Balance | Date |
| schemes | Ordinary | Ordinary | Ordinary | of | of |
| | Share | Share | Share | Ordinary | admission |
| | options | options | options | Shares | |
| | originally | forfeited | admitted | options | |
| | admitted & | during | under | in the | |
| | share | the | scheme | scheme | |
| | options | period' | during | at the | |
| | not issued | | period | end of | |
| | at the | | | the | |
| | start of | | | period | |
| | the period | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 119,000 | 56,500 | - | 62,500 | 05/09/08 |
| Plan 'A' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 196,000 | 23,500 | - | 172,500 | 05/09/08 |
| Plan 'B' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 218,333 | 133,333 | - | 85,000 | 05/09/08 |
| Plan 'C' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 150,000 | 150,000 | - | - | 05/09/08 |
| Plan 'D' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 1,252,500 | 419,167 | - | 833,333 | 05/09/08 |
| Plan 'E' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 50,000 | - | - | 50,000 | 05/09/08 |
| Plan 'F' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 241,667 | 91,667 | - | 150,000 | 05/09/08 |
| Plan 'G' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | - | - | - | - | 05/09/08 |
| Plan 'H' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 135,000 | 26,667 | - | 135,000 | 05/03/09 |
| Plan 'I' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 7,848,750 | 807,709 | - | 7,041,041 | 09/09/09 |
| Plan 'J' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | 300,000 | - | - | 300,000 | 09/09/09 |
| Plan 'K' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
| Share Option | - | - | 100,000 | 100,000 | 08/06/10 |
| Plan 'L' | | | | | |
+----------------+------------+-----------+----------+-----------+-----------+
-ENDS-
For further information, please contact:
+------------------------------------+--------------------------+
| Medicsight plc | |
+------------------------------------+--------------------------+
| Allan Rowley, CEO | Tel: +44 (0)207 605 |
| | 7950 |
+------------------------------------+--------------------------+
| | www.medicsight.com |
+------------------------------------+--------------------------+
| Daniel Stewart & Co | |
+------------------------------------+--------------------------+
| Simon Leathers / Emma Earl | Tel: +44 (0) 207 776 |
| | 6550 |
+------------------------------------+--------------------------+
| | www.danielstewart.co.uk |
+------------------------------------+--------------------------+
Media enquiries:
+-------------------------------------+------------------------+
| Abchurch | |
+-------------------------------------+------------------------+
| | www.abchurch-group.com |
+-------------------------------------+------------------------+
| Heather Salmond | Tel: +44 (0) 207 398 |
| | 7704 |
+-------------------------------------+------------------------+
| heather.salmond@abchurch-group.com | |
+-------------------------------------+------------------------+
| Simone Elviss | Tel: +44 (0) 207 398 |
| | 7728 |
+-------------------------------------+------------------------+
| simone.elviss@abchurch-group.com | |
+-------------------------------------+------------------------+
| Quincy Allan | Tel: +44 (0) 207 398 |
| | 7710 |
+-------------------------------------+------------------------+
| quincy.allan@abchurch-group.com | |
+-------------------------------------+------------------------+
Notes to editors
Medicsight plc is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's CAD software has been validated using one of the world's
largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly
integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 2000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This can be
critical for diagnosis and the management of patient outcomes as early detection
of disease greatly increases the probability of successful treatment and a
positive therapeutic outcome. In addition to supporting individual radiologists
CAD also has the potential to help standardise CT interpretation across both
individuals and institutions thereby supporting population based screening
programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUCUQUPUGAP
Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
